Highlights

  • Firebrick Pharma (ASX:FRE) has introduced Nasodine Nasal Spray in the United States, Singapore and Fiji.
  • A New Zealand composition patent granted in June 2026 extends specified Nasodine protection to 2041.
  • FY25 product revenue was AUD 293,422, versus AUD 14,522 in FY24.
  • FY25 operating cash outflows totalled AUD 1.78 million, compared with AUD 2.34 million in FY24.

Firebrick Pharma Limited (ASX:FRE), an Australian pharmaceutical company developing povidone-iodine products for respiratory health, continues to build international distribution for its Nasodine range while progressing intellectual-property protection. At the time of writing this article on 19 October 2026, the shares were quoted at AUD 0.028, down 15.15% during today’s trading session. The quoted movement is a trading snapshot, not evidence of a particular response to any earlier company announcement. The company’s commercial arrangements, patent portfolio and funding requirements remain central to assessing its operating position.

Company Business

Firebrick develops and commercialises formulations based on povidone-iodine, an antimicrobial ingredient. Its principal product is Nasodine Nasal Spray, containing 0.5% povidone-iodine. The company has marketed the nasal spray in the United States, Singapore and Fiji, using a combination of distribution and licensing arrangements. Its business also includes development of related products, including Nasodine Throat Spray. The company’s operating model increasingly relies on partners to undertake market-specific distribution and promotional activities rather than maintaining equivalent direct-selling operations in every country.

The distinction between sales in a particular overseas market and regulatory authorisation elsewhere is material. Market entry depends on local product rules, permitted claims, import arrangements and distributor execution. Firebrick’s own website states that Nasodine is not approved in Australia. The company’s geographic expansion therefore does not imply uniform approval, availability or product positioning across jurisdictions.

Recent Development

In June 2026, Firebrick announced that New Zealand had granted a patent for its Nasodine pharmaceutical composition, following earlier grants in Australia and South Africa. The patent covers specified formulation characteristics and expires in June 2041. Applications were also pending in several other jurisdictions at the time of that announcement. A granted patent protects the claims covered by that patent in its jurisdiction; it does not itself provide product marketing approval or establish commercial sales.

In August 2025, Firebrick executed a licensing and distribution agreement with Innorini covering Singapore, Malaysia, Brunei and Mauritius. The agreement transferred promotion and distribution responsibilities in the territory to the licensee and provided for Innorini to bear marketing costs from January 2026. Approvals for additional countries within the territory remained subject to the relevant local processes. The company has also reported plans to broaden its Nasodine product range and extend its presence in Southeast Asia.

The corporate website identifies the introduction of a throat spray in Singapore and an Indonesian regulatory approval among its 2026 developments. These steps add potential channels and products, although the timing and scale of recognised revenue depend on actual orders, contractual terms and commercial implementation.

Financial Performance and Sector Context

Firebrick’s audited FY25 annual report recorded revenue from Nasodine sales of AUD 293,422, compared with AUD 14,522 in FY24. The increase reflected the early commercialisation stage and a relatively small comparison base. The company remained loss-making, with its net loss widening to AUD 2.63 million in FY25 from AUD 1.18 million in FY24. Revenue growth therefore did not translate into profitability during that reporting period.

At 30 June 2025, cash and cash equivalents totalled AUD 983,350, compared with AUD 824,776 a year earlier. Net operating cash outflows were AUD 1.78 million in FY25, versus AUD 2.34 million in FY24. Financing inflows contributed to the year-end cash position. The company subsequently reported an AUD 800,000 placement in August 2026; that transaction should be assessed alongside later cash-flow disclosures rather than combined with FY25 balances as though they belonged to the same reporting date.

The relevant industry setting is characterised by country-specific regulation, product evidence requirements, manufacturing controls and distribution economics. Commercialisation of respiratory-health products also depends on how local authorities classify permitted uses and claims. These factors can influence launch timing, marketing expenditure and the division of costs between Firebrick and its partners.

Risks to Consider

Key risks include additional funding needs before sales cover expenses, potential dilution from equity raisings, and uncertainty around the pace of distributor-generated revenue. Regulatory requirements differ by market, while new formulations or indications may require additional evidence. Earlier clinical development has also involved inconsistent trial outcomes: a Phase 3 common-cold study reported in 2023 did not meet its primary endpoint. Patent grants do not eliminate the commercial and regulatory risks surrounding a product.

What to Watch Next

Future quarterly cash-flow reports will indicate receipts from customers, operating expenditure and available funding. Company updates on distribution in Singapore and other Asian markets will help distinguish completed regulatory and commercial milestones from intended launches. Further information on throat-spray uptake, new partner agreements and the status of patent applications would also clarify how the Nasodine portfolio is developing. Any changes in marketing responsibilities or licensing economics could affect the cost profile.

Key Insights

Firebrick has progressed from development into commercial sales across selected overseas markets, with its Nasodine franchise supported by distribution relationships and formulation patents. The audited FY25 accounts showed a growing but limited revenue base, an increased statutory loss and continued cash consumption. Subsequent product and market developments provide operational matters to monitor, while later financial disclosures remain important for measuring the funding position and commercial conversion of those activities.